Profund Advisors LLC Has $373,000 Holdings in Prothena Co. plc (NASDAQ:PRTA)

Profund Advisors LLC reduced its holdings in Prothena Co. plc (NASDAQ:PRTA) by 61.4% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 18,073 shares of the biotechnology company’s stock after selling 28,805 shares during the quarter. Profund Advisors LLC’s holdings in Prothena were worth $373,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Boxer Capital LLC grew its holdings in Prothena by 6.4% during the fourth quarter. Boxer Capital LLC now owns 665,000 shares of the biotechnology company’s stock valued at $24,166,000 after purchasing an additional 40,000 shares during the period. Vanguard Group Inc. increased its position in shares of Prothena by 5.1% during the 1st quarter. Vanguard Group Inc. now owns 1,125,283 shares of the biotechnology company’s stock valued at $27,873,000 after purchasing an additional 54,728 shares during the last quarter. Armistice Capital LLC purchased a new position in shares of Prothena during the fourth quarter worth approximately $10,103,000. Price T Rowe Associates Inc. MD increased its holdings in shares of Prothena by 10.9% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,237,351 shares of the biotechnology company’s stock worth $153,986,000 after buying an additional 417,338 shares during the period. Finally, SG Americas Securities LLC lifted its position in Prothena by 226.4% in the second quarter. SG Americas Securities LLC now owns 54,572 shares of the biotechnology company’s stock valued at $1,126,000 after purchasing an additional 37,852 shares during the last quarter. 97.08% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms have commented on PRTA. Oppenheimer lowered their price target on Prothena from $66.00 to $62.00 and set an “outperform” rating for the company in a research report on Wednesday, August 14th. StockNews.com raised Prothena from a “sell” rating to a “hold” rating in a research report on Monday, August 12th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Prothena in a report on Monday, August 12th. Finally, Royal Bank of Canada reduced their price target on shares of Prothena from $28.00 to $24.00 and set a “sector perform” rating for the company in a research note on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat, Prothena has an average rating of “Moderate Buy” and a consensus price target of $62.86.

Prothena Stock Down 1.4 %

Shares of NASDAQ PRTA opened at $20.14 on Friday. The business has a fifty day simple moving average of $21.59 and a two-hundred day simple moving average of $22.04. The firm has a market cap of $1.08 billion, a PE ratio of -6.20 and a beta of 0.18. Prothena Co. plc has a twelve month low of $18.69 and a twelve month high of $55.89.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.01) by $2.23. The business had revenue of $132.01 million for the quarter, compared to analyst estimates of $10.73 million. Prothena had a negative return on equity of 9.00% and a negative net margin of 23.44%. The company’s revenue was up 3184.7% on a year-over-year basis. During the same period in the prior year, the company earned ($1.03) earnings per share. On average, research analysts expect that Prothena Co. plc will post -2.31 earnings per share for the current year.

About Prothena

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease.